ATE347377T1 - Polymer-stabilisierte neuropeptide - Google Patents

Polymer-stabilisierte neuropeptide

Info

Publication number
ATE347377T1
ATE347377T1 AT00978902T AT00978902T ATE347377T1 AT E347377 T1 ATE347377 T1 AT E347377T1 AT 00978902 T AT00978902 T AT 00978902T AT 00978902 T AT00978902 T AT 00978902T AT E347377 T1 ATE347377 T1 AT E347377T1
Authority
AT
Austria
Prior art keywords
polymer
neuropeptides
stabilized
blood
passing
Prior art date
Application number
AT00978902T
Other languages
English (en)
Inventor
Michael David Bentley
Michael James Roberts
Original Assignee
Nektar Therapeutics Al Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nektar Therapeutics Al Corp filed Critical Nektar Therapeutics Al Corp
Application granted granted Critical
Publication of ATE347377T1 publication Critical patent/ATE347377T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
AT00978902T 1999-10-04 2000-10-04 Polymer-stabilisierte neuropeptide ATE347377T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15750399P 1999-10-04 1999-10-04
US16658999P 1999-11-19 1999-11-19

Publications (1)

Publication Number Publication Date
ATE347377T1 true ATE347377T1 (de) 2006-12-15

Family

ID=26854193

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00978902T ATE347377T1 (de) 1999-10-04 2000-10-04 Polymer-stabilisierte neuropeptide

Country Status (11)

Country Link
US (6) US20020013266A1 (de)
EP (1) EP1221975B1 (de)
JP (1) JP4027663B2 (de)
KR (1) KR100619612B1 (de)
AT (1) ATE347377T1 (de)
AU (1) AU782298B2 (de)
CA (1) CA2385533C (de)
DE (1) DE60032255T2 (de)
ES (1) ES2275561T3 (de)
MX (1) MXPA02003176A (de)
WO (1) WO2001024831A2 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100361933B1 (ko) * 1993-09-08 2003-02-14 라 졸라 파마슈티칼 컴파니 화학적으로정의된비중합성결합가플랫폼분자및그것의콘주게이트
US6458953B1 (en) * 1998-12-09 2002-10-01 La Jolla Pharmaceutical Company Valency platform molecules comprising carbamate linkages
WO2001024831A2 (en) 1999-10-04 2001-04-12 Shearwater Corporation Polymer stabilized neuropeptides
CN1939538A (zh) * 2001-05-17 2007-04-04 应用研究系统Ars股份公司 骨桥蛋白在制备治疗和/或预防神经疾病的药物中的用途
JP4838968B2 (ja) * 2001-09-28 2011-12-14 参天製薬株式会社 薬物−ポリエチレングリコール結合体を含有する眼組織内注入剤
US7579444B2 (en) * 2004-06-30 2009-08-25 Nektar Therapeutics Al, Corporation Polymer-factor IX moiety conjugates
US8420602B2 (en) * 2004-09-14 2013-04-16 Landon C. G. Miller Endocannabinoid conjugate and a pharmaceutical composition for treatment of neuronal disorders
TWI515007B (zh) 2006-01-05 2016-01-01 美國猶他大學研究基金會 改善以神經系統為標的之藥劑之性質之方法及組合物
PL381925A1 (pl) * 2007-03-07 2008-09-15 Andrzej W. Lipkowski Zastosowanie peptydu i przeciwbólowy środek farmaceutyczny
US8173666B2 (en) 2007-03-12 2012-05-08 Nektar Therapeutics Oligomer-opioid agonist conjugates
US10512644B2 (en) 2007-03-12 2019-12-24 Inheris Pharmaceuticals, Inc. Oligomer-opioid agonist conjugates
US10540861B2 (en) * 2007-12-20 2020-01-21 Ncr Corporation Sustained authentication of a customer in a physical environment
AU2009292631A1 (en) * 2008-09-16 2010-03-25 Nektar Therapeutics Pegylated opioids with low potential for abuse
US20120195847A1 (en) * 2008-09-19 2012-08-02 Nektar Therapeutics Polymer conjugates of biphalin peptides
WO2010033223A1 (en) * 2008-09-19 2010-03-25 Nektar Therapeutics Polymer conjugates of opioid growth factor peptides
CA2737040C (en) * 2008-09-19 2017-05-02 Nektar Therapeutics Polymer conjugates of therapeutic peptides
DE202009004764U1 (de) * 2009-04-30 2010-09-16 Hettich Holding Gmbh & Co. Ohg Siphon und Möbel
ME02206B (me) 2010-05-27 2016-02-20 Centocor Ortho Biotech Inc Receptor insulinu-sličnog faktora rasta 1 vezujući peptidi
US8524215B2 (en) * 2010-08-02 2013-09-03 Janssen Biotech, Inc. Absorbable PEG-based hydrogels
CA2858811A1 (en) 2010-12-15 2012-06-12 Neuroadjuvants, Inc. Neuropeptide analogs, compositions, and methods for treating pain
WO2012095523A1 (en) * 2011-01-13 2012-07-19 Theralpha Analgesic composition for transbuccal administration
EP2476410A1 (de) * 2011-01-13 2012-07-18 Theralpha Analgetische Peptid enthaltende Zusammensetzung zur transbuccalen Verabreichung
WO2015152182A1 (ja) * 2014-03-31 2015-10-08 日油株式会社 環状ベンジリデンアセタールリンカーを有する親水性ポリマー誘導体
CN111220676B (zh) * 2019-11-13 2022-11-29 上海药明生物技术有限公司 利用毛细管电泳技术检测含聚乙二醇的蛋白质样品纯度的方法

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4462941A (en) * 1982-06-10 1984-07-31 The Regents Of The University Of California Dynorphin amide analogs
US4468383A (en) * 1982-09-29 1984-08-28 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Service Dimeric enkephalins
US4518711A (en) * 1983-05-16 1985-05-21 Gibson-Stephens Institute Conformationally constrained cyclic enkephalin analogs with delta receptor specificity
US4684624A (en) * 1983-12-22 1987-08-04 Yoshio Hosobuchi Method of treating cerebral ischemia
IT206701Z2 (it) * 1985-08-02 1987-10-01 Gate Spa Ventilatore assiale particolarmente per autoveicoli
US4902505A (en) * 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US5017689A (en) * 1989-07-06 1991-05-21 Arizona Technology Development Corporation Dynorphin analogs specific for kappa opioid receptors
US5286637A (en) * 1989-08-07 1994-02-15 Debiopharm, S.A. Biologically active drug polymer derivatives and method for preparing same
US5527527A (en) * 1989-09-07 1996-06-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
US6552170B1 (en) * 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US5112596A (en) 1990-04-23 1992-05-12 Alkermes, Inc. Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability
ES2117642T3 (es) * 1990-05-10 1998-08-16 Bechgaard Int Res Preparado farmaceutico que contiene n-glicofuroles y n-etilen glicoles.
US5827819A (en) * 1990-11-01 1998-10-27 Oregon Health Sciences University Covalent polar lipid conjugates with neurologically active compounds for targeting
US5326751A (en) * 1992-06-26 1994-07-05 Arizona Board Of Regents On Behalf Of The University Of Arizona Enkephalin analogs
EP0599303A3 (de) * 1992-11-27 1998-07-29 Takeda Chemical Industries, Ltd. Peptide-Konjugate
US5359030A (en) * 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US5681811A (en) * 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
AU7113594A (en) * 1993-06-21 1995-01-17 Enzon, Inc. Site specific synthesis of conjugated peptides
US5880131A (en) 1993-10-20 1999-03-09 Enzon, Inc. High molecular weight polymer-based prodrugs
US5629384A (en) * 1994-05-17 1997-05-13 Consiglio Nazionale Delle Ricerche Polymers of N-acryloylmorpholine activated at one end and conjugates with bioactive materials and surfaces
US5626862A (en) 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
US5932462A (en) * 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5670477A (en) * 1995-04-20 1997-09-23 Joseph F. Poduslo Method to enhance permeability of the blood/brain blood/nerve bariers to therapeutic agents
US5948389A (en) * 1995-06-07 1999-09-07 El Khoury & Stein, Ltd. Method of enhancing the analgesic efficacy of locally and topically administered opioids and other local anesthetics
US5990237A (en) * 1997-05-21 1999-11-23 Shearwater Polymers, Inc. Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines
US5945510A (en) 1997-05-21 1999-08-31 University Of Maryland, Baltimore Substantially pure zonulin, a physiological modulator of mammalian tight junctions
IL136680A0 (en) * 1997-12-12 2001-06-14 Macromed Inc Heterofunctionalized star-shaped poly(ethylene glycols) for protein modification
ATE268609T1 (de) * 1998-03-12 2004-06-15 Nektar Therapeutics Al Corp Polyethylenglycolderivate mit benachbarten reaktiven gruppen
WO1999055376A1 (en) * 1998-04-28 1999-11-04 Applied Research Systems Ars Holding N.V. Peg-lhrh analog conjugates
US6703381B1 (en) * 1998-08-14 2004-03-09 Nobex Corporation Methods for delivery therapeutic compounds across the blood-brain barrier
US6309633B1 (en) * 1999-06-19 2001-10-30 Nobex Corporation Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
KR100345214B1 (ko) * 1999-08-17 2002-07-25 이강춘 생체적합성 고분자가 수식된 펩타이드의 비점막 전달
US6713454B1 (en) * 1999-09-13 2004-03-30 Nobex Corporation Prodrugs of etoposide and etoposide analogs
WO2001024831A2 (en) * 1999-10-04 2001-04-12 Shearwater Corporation Polymer stabilized neuropeptides
US6413507B1 (en) * 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
WO2003032990A2 (en) * 2001-10-18 2003-04-24 Nektar Therapeutics Al, Corporation Polymer conjugates of opioid antagonists

Also Published As

Publication number Publication date
CA2385533A1 (en) 2001-04-12
KR100619612B1 (ko) 2006-09-01
EP1221975A2 (de) 2002-07-17
WO2001024831A9 (en) 2002-11-14
MXPA02003176A (es) 2002-09-30
US20110257106A1 (en) 2011-10-20
AU782298B2 (en) 2005-07-14
US20030139346A1 (en) 2003-07-24
WO2001024831A3 (en) 2002-03-07
AU1631201A (en) 2001-05-10
KR20020032604A (ko) 2002-05-03
ES2275561T3 (es) 2007-06-16
DE60032255T2 (de) 2007-06-28
US20020013266A1 (en) 2002-01-31
US8008435B2 (en) 2011-08-30
JP2003511357A (ja) 2003-03-25
JP4027663B2 (ja) 2007-12-26
CA2385533C (en) 2008-03-25
EP1221975B1 (de) 2006-12-06
US8440623B2 (en) 2013-05-14
WO2001024831A2 (en) 2001-04-12
US20040038899A1 (en) 2004-02-26
DE60032255D1 (de) 2007-01-18
US20020019340A1 (en) 2002-02-14
US20030144207A1 (en) 2003-07-31

Similar Documents

Publication Publication Date Title
DE60032255D1 (de) Polymer-stabilisierte neuropeptide
CO5540371A2 (es) Administracion pulmonar de insulina quimicamente modificada
ATE263579T1 (de) Abgabe von polyethylene glycol-molekül- konjugaten aus abbaubarem hydrogel
OA09760A (fr) "Conjugués de protéine et de polyéthylène glycol".
NO20023315D0 (no) G-CSF konjugater
DK0973819T3 (da) Ikke-antigene forgrenede polymerkonjugater
ATE359829T1 (de) Wasserlösliche polymerkonjugate von retinoesäure
YU56693A (sh) Konjugati peg-interferon
DE60006100D1 (de) Lang wirkende insulinotrope peptide
MA25875A1 (fr) Nouveaux derives de l'acide aminodicarboxylique presentant des proprietes pharmaceutiques.
BR0210530A (pt) Composições farmacêuticas de drogas e poìimeros acìdicos neutralizados
EP1078079A4 (de) Methoden zur gestaltung von proteingebundenen lipidischen mikropartikeln und verbindungen damit
ATE287705T1 (de) Wärmegellierende bioabbaubare wässrige polymerlösung
RS49533B (sr) Interferonski konjugati
PT1196443E (pt) Conjugados de eritropoietina com polietileno glicol
BR0009472A (pt) Antagonistas de lhrh com propriedades desolubilidade aperfeiçoadas
ATE395049T1 (de) Verbesserte pharmazeutische zusammensetzungen von hiv-proteasehemmern
ATE273684T1 (de) Eingekapselte wasserdispergierbare perfluoroetherpolymere
RU93057952A (ru) Биологический активный макромолекулярный конъюгат, гидразинсодержащие конъюгаты полипептидов и гликополипептидов с полимерами
YU29492A (sh) Konjugati proteina sa polietilenom

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties